• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

CMS Finalizes 2025 Rates for Medicare Advantage and Part D Plans


Market shares have fallen for CVS, UnitedHealth Group and more following the announcement.

 © NajmiArif - stock.adobe.com

medicare advantage and stethoscope © NajmiArif - stock.adobe.com

A change in Medicare Advantage announced Monday has sparked concern by trade groups and caused stocks of leading health insurers to fall. Health insurance trade groups such as AHIP, as well as stocks from CVS, UnitedHealth Group and Centene all reported falling stocks Tuesday.

CMS has finalized the 2025 calendar year rate for Medicare Advantage and Medicare Part D Prescription Drug Programs.

Medicare Advantage is a privately run healthcare insurance plan contracted by Medicare. More than half of Medicare beneficiaries are enrolled in Medicare Advantage, according to KFF.

The announcement states that for the 33 million Medicare Advantage beneficiaries, payment rates from the government to Medicare Advantage plans are expected to increase by 3.7%, or more than $16 billion, from 2024 to 2025. In addition, in 2025, the federal government will pay between $500 to $600 billion to private health plans. The Medicare Advantage benchmark rate will also decrease by 0.16% in 2025.

President and CEO of AHIP Mike Tuffin released a statement in response to Monday’s announcement.

“These policies will put even more pressure on the benefits and premiums of 33 million Medicare Advantage beneficiaries who will be renewing their coverage this fall,” Tuffin said in an AHIP press release. “It is important to note that the Medicare Advantage and Part D programs are already undergoing a number of significant regulatory and legislative changes. Moreover, cost of caring for Medicare Advantage beneficiaries is steadily rising.”

At the beginning of March, the AHIP also wrote a letter that compiled insurer concerns and addressed it to CMS.

“The estimate does not reflect higher utilization and cost trends in the healthcare market that are expected to continue into 2025,” Tuffin writes in the letter. “Based on a recent AHIP survey, MA plans cost growth in 2023 was more than 7%, on average, in all quarters of the year and spiked above 8% in the fourth quarter."

CMS is accepting comments and requests for Medicare information until May 29.

Related Videos
Video 2 - "Bridging Care Gaps with Prescription Digital Therapeutics"
Video 1 - "Overview of Prescription Digital Therapeutics and Impact on Clinical Practice"
Video 4 - "Payer Challenges in Evaluating Digital Therapeutics"
Video 3 - "Industry Collaboration in Shaping Digital Therapeutics Standards"
Video 6 - "Key Takeaways and Unmet Needs in Diabetes Treatment"
Video 5 - "Allocation of Investment and Value-Based Arrangements in Diabetes Care "
Video 4 - "Diabetes Prevention and Reducing Disparities Across Populations"
Video 3 - "Integrating CGMs into Diabetes Treatment Programs"
Related Content
© 2024 MJH Life Sciences

All rights reserved.